Drug Profile

BGB 45035

Alternative Names: BGB-45035

Latest Information Update: 12 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BeiGene
Developer BeOne Medicines
Class Antirheumatics; Skin disorder therapies
Mechanism of Action IRAK4 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Rheumatoid arthritis
Phase I Atopic dermatitis; Prurigo nodularis

Most Recent Events

28 May 2026 BeiGene terminates a phase II trial in Rheumatoid arthritis (Treatment-experienced) in China (PO) due to unfavoured benefit/risk profile (NCT07100938)
06 Nov 2025 BeiGene plans a phase II trial for Atopic dermatitis in first half of 2026
24 Oct 2025 Pharmacokinetics, pharmacodynamic and adverse event data from a phase I trial in Atopic dermatitis presented at the ACR Convergence 2025 (ACR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com